Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advanced Micro Devices
AMD
|
+$1.32B |
| 2 |
AstraZeneca
AZN
|
+$733M |
| 3 |
Microsoft
MSFT
|
+$728M |
| 4 |
Cadence Design Systems
CDNS
|
+$720M |
| 5 |
Moody's
MCO
|
+$359M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alcon
ALC
|
+$1.43B |
| 2 |
Estee Lauder
EL
|
+$872M |
| 3 |
Eli Lilly
LLY
|
+$626M |
| 4 |
Netflix
NFLX
|
+$521M |
| 5 |
UnitedHealth
UNH
|
+$466M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.19% |
| 2 | Consumer Discretionary | 19.62% |
| 3 | Healthcare | 16.16% |
| 4 | Financials | 9.12% |
| 5 | Communication Services | 8.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
DHR.PRB
426
DELISTED
Danaher Corporation 5.00% Mandatory Convertible Preferred Stock, Series B
DHR.PRB
| $6.21M | 0.01% |
4,872
| – | – |
|
427
Xylem
XYL
$28.2B
| $6.2M | 0.01% |
59,204
-23,309
| -28% | -$2.43M |
|
428
Corpay
CPAY
$26B
| $6.18M | 0.01% |
29,311
-2,775
| -9% | -$563K |
|
429
Service Corp International
SCI
$11.6B
| $6.09M | 0.01% |
88,480
-38,323
| -30% | -$2.65M |
|
430
General Mills
GIS
$19.3B
| $6.07M | 0.01% |
71,058
+55,485
| +356% | +$4.43M |
|
431
NextDecade
NEXT
$1.81B
| $6M | 0.01% |
+1,208,125
| New | +$7.02M |
|
432
Hudbay
HBM
$11.7B
| $5.87M | 0.01% |
1,119,645
+274,675
| +33% | +$1.44M |
|
433
National Vision
EYE
$1.8B
| $5.62M | 0.01% |
298,348
-102,888
| -26% | -$3.35M |
|
434
Mineralys Therapeutics
MLYS
$2.38B
| $5.57M | 0.01% |
+355,475
| New | +$5.98M |
|
435
SiTime
SITM
$20.6B
| $5.44M | 0.01% |
+38,256
| New | +$4.7M |
|
|
CBAY
436
DELISTED
Cymabay Therapeutics
CBAY
| $5.44M | 0.01% |
+623,663
| New | +$4.99M |
|
437
Hannon Armstrong Sustainable Infrastructure Capital
HASI
$4.89B
| $5.38M | ﹤0.01% |
188,056
-275
| -0.1% | -$8.7K |
|
438
Diageo
DEO
$51.6B
| $5.32M | ﹤0.01% |
29,355
-9,376
| -24% | -$1.65M |
|
439
Canadian Pacific Kansas City
CP
$79.3B
| $5.24M | ﹤0.01% |
68,108
-1,636
| -2% | -$126K |
|
440
Lifestance Health
LFST
$4.07B
| $5M | ﹤0.01% |
+673,274
| New | +$3.73M |
|
441
EQT Corp
EQT
$32.3B
| $4.94M | ﹤0.01% |
154,794
-375,342
| -71% | -$12M |
|
442
Plains All American Pipeline
PAA
$16.6B
| $4.84M | ﹤0.01% |
387,796
| – | – |
|
|
LTHM
443
DELISTED
Livent Corporation
LTHM
| $4.77M | ﹤0.01% |
219,467
+70,756
| +48% | +$1.64M |
|
444
State Street SPDR S&P Metals & Mining ETF
XME
$4.22B
| $4.76M | ﹤0.01% |
89,502
+6,965
| +8% | +$379K |
|
|
GOGN
445
DELISTED
GoGreen Investments Corporation
GOGN
| $4.54M | ﹤0.01% |
452,817
| – | – |
|
446
TXO Partners LP
TXO
$745M
| $4.38M | ﹤0.01% |
+189,481
| New | +$4.36M |
|
447
Hess Midstream
HESM
$5.13B
| $3.88M | ﹤0.01% |
133,902
| – | – |
|
448
Seres Therapeutics
MCRB
$47.9M
| $3.77M | ﹤0.01% |
33,237
-185
| -0.6% | -$20K |
|
|
NESR
449
National Energy Services Reunited Corp
NESR
$2.91B
| $3.26M | ﹤0.01% |
620,256
-1,747
| -0.3% | -$11.5K |
|
|
LPRO
450
DELISTED
Open Lending Corp
LPRO
| $2.64M | ﹤0.01% |
374,756
-963,818
| -72% | -$7.5M |
|
Similar funds
Jennison Associates's Q1 2023 Portfolio in Review
As of Q1 2023, Jennison Associates held 644 positions worth $109B, up 10% from $98.7B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Jennison Associates withdrew a net $3.94B in Q1 2023, closing 63 positions and reducing 280 holdings. Its most notable exit was Alcon, an estimated $1.43B position sold in full.
By sector, the portfolio is most concentrated in Technology at 33% of assets, up from 26% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, Jennison Associates opened a new position in Advanced Micro Devices worth $1.59B.
- Jennison Associates's largest Q1 2023 buy was Advanced Micro Devices: 16,272,765 shares worth $1.59B.
- Jennison Associates added most to AstraZeneca in Q1 2023, an estimated $733M increase.
- Jennison Associates's biggest Q1 2023 reduction was Estee Lauder, cutting an estimated $872M.
- Jennison Associates fully exited Alcon in Q1 2023, selling an estimated $1.43B.
- Jennison Associates's ten largest holdings make up 39% of its $109B portfolio in Q1 2023.
- Jennison Associates opened 73 new positions and closed 63 in Q1 2023.
- Jennison Associates's portfolio value rose 10% quarter-over-quarter to $109B.
Based on Jennison Associates's 13F filing for Q1 2023, filed 26 Apr 2023.